Cagri + Sema (2.5mg+2.5mg) – 5mg

Cagri + Sema – 2.5mg + 2.5mg – 5mg – 10 Vials

Product Overview

Cagri + Sema is a combination of cagrilintide and semaglutide, two compounds investigated for their roles in appetite regulation and metabolic processes.

Cagrilintide is a long-acting amylin analogue, while semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The combination has been studied in clinical research, but this does not establish the safety or regulatory approval of every combined formulation or vial presentation.

This listing describes a product labeled as 2.5mg cagrilintide + 2.5mg semaglutide, with a combined listed amount of 5mg.

Product Details

• Product Name: Cagri + Sema
• Active Ingredients: Cagrilintide + Semaglutide
• Cagrilintide Amount: 2.5mg
• Semaglutide Amount: 2.5mg
• Combined Listed Amount: 5mg
• Package Quantity: 10 vials
• Product Category: Investigational Peptide Combination
• Formulation: Confirm with supplier
• Manufacturer: Confirm with supplier
• Storage Requirements: Follow verified manufacturer documentation

Scientific Background

Cagrilintide is an amylin analogue investigated for its role in appetite-related signaling and metabolic regulation.

Semaglutide acts on GLP-1 receptors and is available in approved prescription formulations for specific medical indications. Those approvals do not automatically apply to unverified combination products.

The combination of cagrilintide and semaglutide has been investigated in clinical studies. However, research findings about the combination do not establish the quality, safety, or effectiveness of this particular product.

Supplier Verification

Before publishing or distributing this product, confirm:

• Whether the 2.5mg + 2.5mg composition applies to each vial or the entire package
• The exact amount of each active ingredient
• Product formulation and concentration
• Manufacturer identity and batch information
• Available quality and composition documentation
• Storage and handling requirements
• Applicable regulatory authorization and restrictions

Important Safety and Regulatory Information

Semaglutide is a prescription medicine in certain approved formulations, while cagrilintide remains investigational. A combined product should not be presented as an approved medicine unless its specific formulation has the required authorization.

This listing is informational only and is not medical advice, a dosing guide, or a recommendation for self-administration. Do not make unsupported claims about weight loss, treatment outcomes, safety, purity, or regulatory approval. Verify the product’s identity, documentation, and legal status before making further claims.